Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma

June 23rd 2025

CHMP issues positive opinion for isatuximab plus VRd in transplant-eligible, newly diagnosed multiple myeloma.

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma

June 23rd 2025

Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Dr van de Donk on Initial Safety and Efficacy Findings From the First-In-Human Study of JNJ-5322 in R/R Multiple Myeloma

June 20th 2025

Niels van de Donk, MD, discusses initial safety and efficacy findings from the first-in-human study of JNJ-5322 in relapsed or refractory multiple myeloma.

Subcutaneous Daratumumab Approaches EU Approval in High-Risk Smoldering Myeloma

June 20th 2025

The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.

Dr Landgren on the Efficacy of Dara-KRd in Newly Diagnosed Myeloma Regardless of Transplant Eligibility

June 18th 2025

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

Dr Lin on the Rationale for Evaluating Cilta-Cel–Associated Late-Onset Toxicities in Myeloma

June 18th 2025

Yi Lin, MD, PhD, discusses the rationale for evaluating the onset of delayed toxicities following cilta-cel infusion in patients with multiple myeloma.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Dr Krishnan on the Potential Clinical Impact of Trispecific Antibodies in R/R Multiple Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses the potential clinical impact of trispecific antibodies in the management of relapsed/refractory multiple myeloma.

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

June 16th 2025

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

June 16th 2025

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma

June 15th 2025

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.

Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression

June 15th 2025

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

June 14th 2025

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma

June 14th 2025

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma

June 14th 2025

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

June 4th 2025

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

June 4th 2025

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.